Carolina Maciel

Dr. Carolina Maciel

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2019 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
CSC. William Shuttleworth
C. William Shuttleworth
RAR. David Andrew
R. David Andrew
YAYama Akbari
Yama Akbari
CACenk Ayata
Cenk Ayata
RBRamani Balu
Ramani Balu
JHJed A. Hartings
Jed A. Hartings

1 August 2021 in Resuscitation
Verified
Journal Article
Closed access
RBRachel Beekman
Rachel Beekman
CMCarolina Maciel
Carolina Maciel
COCora H. Ormseth
Cora H. Ormseth
SZSonya E. Zhou
Sonya E. Zhou
DGDaniela Galluzzo
Daniela Galluzzo
EGEmily J. Gilmore
Emily J. Gilmore

1 October 2018 in Resuscitation
Verified
Journal Article
Closed access
MDMonica B. Dhakar
Monica B. Dhakar
ASAdithya Sivaraju
Adithya Sivaraju
CMCarolina Maciel
Carolina Maciel
TYTeddy S. Youn
Teddy S. Youn
NGNicolas Gaspard
Nicolas Gaspard
EGEmily J. Gilmore
Emily J. Gilmore

9 January 2020 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
CMCarolina Maciel
Carolina Maciel
TYTeddy S. Youn
Teddy S. Youn
MBMary M. Barden
Mary M. Barden
MDMonica B. Dhakar
Monica B. Dhakar
SZSonya E. Zhou
Sonya E. Zhou
DGDavid M. Greer
David M. Greer

6 August 2016 in Current Neurology and Neuroscience Reports
Verified
Journal Article
Open access
PDF file
CMCarolina Maciel
Carolina Maciel
DGDavid M. Greer
David M. Greer
End-organ failure is associated with high mortality and morbidity, in addition to increased health care costs. Organ transplantation is the only definitive treatment that can improve survival and quality of life in such patients; however, due to the persistent mismatch between organ supply and demand, waiting lists continue to grow across the world. Careful intensive care management of the potential organ donor with goal-directed therapy has the potential to optimize organ function and improve donation yield.

22 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JKJason Katz
Jason Katz
KOKent Owusu
Kent Owusu
INIlisa Nussbaum
Ilisa Nussbaum
RBRachel Beekman
Rachel Beekman
NDNicholas DeFilippo
Nicholas DeFilippo
CMCarolina Maciel
Carolina Maciel
Background: Status epilepticus (SE) carries an exceedingly high mortality and morbidity, often warranting an aggressive therapeutic approach. Recently, the implementation of a ketogenic diet (KD) in adults with refractory and super-refractory SE has been shown to be feasible and effective. Methods: We describe our experience, including the challenges of achieving and maintaining ketosis, in an adult with new onset refractory status epilepticus (NORSE). Case Vignette: A previously healthy 29-year-old woman was admitted with cryptogenic NORSE following a febrile illness; course was complicated by prolonged super-refractory SE. A comprehensive work-up was notable only for mild cerebral spinal fluid (CSF) pleocytosis, elevated nonspecific serum inflammatory markers, and edematous hippocampi with associated diffusion restriction on magnetic resonance imaging (MRI). Repeat CSF testing was normal and serial MRIs demonstrated resolution of edema and diffusion restriction with progressive hippocampal and diffuse atrophy. She required prolonged therapeutic coma with high anesthetic infusion rates, 16 antiseizure drug (ASD) trials, empiric immunosuppression and partial bilateral oophorectomy. Enteral ketogenic formula was started on hospital day 28. However, sustained beta-hydroxybutyrate levels >2 mmol/L were only achieved 37 days later following a comprehensive adjustment of the care plan. KD was challenging to maintain in the intensive care unit (ICU) and was discontinued due to poor nutritional state and pressure ulcers. KD was restarted again in a non-ICU unit facilitating ASD tapering without re-emergence of SE. Discussion: There are inconspicuous carbohydrates in commonly administered medications for SE including antibiotics, electrolyte repletion formulations, different preparations of the same drug (i.e., parenteral, tablet, or suspension) and even solutions used for oral care―all challenging the use of KD in the hospitalized patient. Tailoring comprehensive care and awareness of possible complications of KD are important for the successful implementation and maintenance of ketosis.